Diabetes device makers are transitioning from core Type 1 cohorts into massive Type 2 and non-insulin markets, supported by expanding reimbursement, AID algorithm adoption, and pharmacy-channel access.
13 tickers·$232.98B market cap
10D-1.74%#689of 1,461 themes/1,461#7of 14 in MedTech/14 MedTech